These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35909007)

  • 1. [Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response].
    Storme S; Debieuvre D; Souquet PJ; Toffart AC; Couraud S
    Rev Mal Respir; 2022 Sep; 39(7):578-586. PubMed ID: 35909007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
    Zapata E; Mennecier B; Leduc C; Chatron E; Quoix E
    Rev Pneumol Clin; 2016 Oct; 72(5):300-304. PubMed ID: 27561974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
    El-Ghazzi N; Lavaud P
    Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
    [No Abstract]   [Full Text] [Related]  

  • 5. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
    Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
    J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
    Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pembrolizumab in adjuvant therapy in non-small cell lung cancers].
    Lefèvre A; Tissot C
    Bull Cancer; 2024 Apr; 111(4):334-336. PubMed ID: 38471995
    [No Abstract]   [Full Text] [Related]  

  • 9. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
    Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.
    Schmalz O; Jacob C; Ammann J; Liss B; Iivanainen S; Kammermann M; Koivunen J; Klein A; Popescu RA
    J Med Internet Res; 2020 Dec; 22(12):e18655. PubMed ID: 33346738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study.
    Darrason M; Chatelain E; Ranchon F; Gervaise C; Duruisseaux M; Couraud S
    Respir Med Res; 2020 Mar; 77():100-105. PubMed ID: 32512522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy and Immunotherapy Combinations for Lung Cancer.
    Agrawal V; Benjamin KT; Ko EC
    Curr Oncol Rep; 2020 Nov; 23(1):4. PubMed ID: 33215306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic strategies in patients undergoing surgery for non-small cell lung cancer. Results of the ESCAP-2011-CPHG study, promoted by the French College of General Hospital Respiratory Physicians (CPHG)].
    Pinquié F; Goupil F; Oster JP; Dixmier A; Renault PA; Lévy A; Mathieu JP; Paillot N; Goutorbe FC; Masson P; Molinier O; Debieuvre D; Grivaux M
    Rev Mal Respir; 2017 Nov; 34(9):976-990. PubMed ID: 29150179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients.
    Yilmaz M; Guven Mese S
    J Oncol Pharm Pract; 2020 Apr; 26(3):761-767. PubMed ID: 31423946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma.
    Martín-Ruiz A; Fiuza-Luces C; Rincón-Castanedo C; Fernández-Moreno D; Gálvez BG; Martínez-Martínez E; Martín-Acosta P; Coronado MJ; Franco-Luzón L; González-Murillo Á; Ramírez M; Provencio M; Lucia A
    Exerc Immunol Rev; 2020; 26():100-115. PubMed ID: 32139351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.